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INTRODUCTION
In the spring of 1943, a 37-year-old Swiss chemist named 
Albert Hofmann had “a peculiar presentiment.” He 
believed that he had missed something in 1938, the year 
when he first synthesized the twenty-fifth compound of 
the lysergic acid diethylamide series, LSD-25. For eight 
years at Sandoz Pharmaceuticals, Hofmann was in charge 
of the ergot project, which involved synthesizing ergota-
mine molecules for the treatment of migraines. On April 
16, 1943, guided by a premonition, Hofmann synthesized 
and ingested a crystalline water-soluble batch of LSD-
25. Shortly thereafter, Hofmann experienced “an unin-
terrupted stream of fantastic images of extraordinary 
plasticity and vividness . . . accompanied by an intense 
kaleidoscopic play of colors” (Stevens, 1987).
Less than thirty years after Hofman’s discovery, the 
Drug Enforcement Agency (DEA) classified LSD and 
other related psychedelics, including psilocybin (the 
psychoactive component found in psilocybin mush-
rooms), as Schedule I, a category for drugs that have 
no known medical use and a high potential for abuse 
(DEA, 2011). As a result, nearly all research on psychedel-
ics was placed on hold until the early 1990s, when sev-
eral investigators received approval from the Food and 
Drug Administration (FDA) to conduct carefully designed 
research trials. In 1995, Rick Strassman, MD, a psychiatrist 
and graduate of Albert Einstein College of Medicine, 
completed a study at the University of New Mexico in 
which he administered N,N-dimethyltryptamine (DMT) 
to 60 volunteers. This was the first clinical research proj-
ect involving a psychedelic drug that the United States 
government had approved and funded in more than 
twenty years (Strassman, 2001).
In the years following this study, with funding from non-
profit research and educational organizations such as 
the Multidisciplinary Association for Psychedelic Studies 
(MAPS), nearly a dozen more clinical research projects on 
psychedelic drugs have been initiated. Multiple investi-
gations involving research questions ranging from the 
use of psilocybin as an end-of-life therapy for terminal 
cancer patients to the use of LSD for the treatment of 
cluster headaches have been completed or are under 
way at institutions such as the Johns Hopkins University 
and New York University (MAPS, 2011). On October 15, 
2011, Horizons, the fifth annual national conference 
on psychedelic research, took place in New York City at 
Judson Memorial Church. Physicians, scientists, scholars, 
and artists gathered to learn about the latest research 
projects from experts in the psychedelics field. The top-
ics of that year’s conference ranged from the treatment 
of post-traumatic stress disorder (PTSD) with the use of 
3,4-methylenedioxymethamphetamine (MDMA) to the 
use of psilocybin as a treatment for depression and anxi-
ety in terminal cancer patients.
SELECTED CONFERENCE PRESENTATIONS
MAPS’ International Psychedelic Clinical Research: The 
Past, Present, and Future, by Berra Yazar-Klosinski, PhD
Berra Yazar-Klosinski, a clinical research associate at 
MAPS, provided an overview of the history of MDMA 
before describing two clinical research projects investi-
gating potential therapeutic properties of the drug. In 
1912, Merck & Co., Inc., first synthesized MDMA, com-
monly referred to as ecstasy, as a blood-clotting agent. 
However, no animal or human testing was conducted on 
MDMA until the early 1950s, when, it is believed, the U.S. 
Air Force tested it as a potential truth serum. MDMA did 
not appear again until the 1970s, when it was found in 
tablets seized in Chicago.
From 1980 to 1985, the physician George Greer syn-
thesized MDMA in the lab of psychopharmacologist 
Alexander Shulgin and conducted more than a hun-
dred therapeutic sessions with 80 individuals with 
the assistance of his wife, Requa Tolbert, a psychiatric 
nurse. They reported that their patients experienced a 
marked improvement in psychiatric disorders, as well as 
improved intimate communication with significant oth-
ers. However, due to the increasing popularity of MDMA 
in underground raves and nightclubs across the United 
States, the DEA classified the drug as Schedule I in the 
spring of 1985.
Seven years later, the FDA agreed to accept proposals 
for the study of MDMA. From 1992 to 1995, Dr. Charles 
Grob conducted a Phase I safety study to investigate the 
drug’s effects on the cardiovascular system. Subsequent 
efforts to obtain approval for a cancer study with MDMA 
were rejected by the FDA until the summer of 1999, 
when formal protests were addressed to senior FDA 
management, arguing that the potential therapeutic 
benefits of MDMA outweighed its potential for abuse. 
In 1999, the FDA approved the first proof-of-principle 
study with MDMA in which a specific potential use of 
the drug would be investigated. In 2003, a Johns Hopkins 
University research team retracted its report in Science 
speculating that ecstasy users face a greater risk of devel-
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oping Parkinson’s disease, after the scientists realized 
they had mistakenly administered methamphetamine 
and not MDMA to all but one of the monkeys used in 
the study (Ricaurte et al., 2003). However, damage to the 
public’s perception of MDMA had already been done.
After discussing the history of MDMA, Dr. Yazar-Klosinski 
explained current FDA recommendations for MAPS-
funded pilot studies involving MDMA-assisted psycho-
therapy to treat patients suffering from PTSD. Current 
studies use two to three therapeutic sessions spaced 
three to five weeks apart in which the patient lies on 
a soft couch in a comfortable room. Investigators have 
found that spacing the sessions several weeks apart 
provides ample time for patients to process their expe-
riences properly. This stands in contrast to most other 
treatment modalities, which require long-term and reg-
ular pharmaceutical intake. After the final therapy ses-
sion, the subjects are monitored to assess lasting positive 
or negative effects and to determine if the patients feel 
compelled to seek MDMA illegally.
The degree of improvement in symptoms of PTSD fol-
lowing treatment with MDMA is measured using the 
Clinician-Administered PTSD Scale (CAPS). In a September 
2008 Phase II U.S. pilot study involving 21 subjects with 
treatment-resistant PTSD resulting from sexual abuse, 
crime, or war, investigators found significant improve-
ment in patients’ CAPS scores after a single session with 
MDMA and psychotherapy versus psychotherapy and 
a placebo (Mithoefer et al., 2011). The subjects’ CAPS 
scores continued to improve for two months after their 
second experimental session. In a similar study in January 
2010 of 12 subjects in Switzerland with treatment- 
resistant PTSD, there was a clinically significant improve-
ment in the experimental group’s CAPS scores, equiva-
lent to that of groups administered other drugs typically 
used for the treatment of PTSD (e.g., Zoloft). In these 
studies, 125 mg of MDMA was given to the experimen-
tal group and 25 mg of MDMA was given to the control 
group as the placebo. Participants in neither the U.S. nor 
the Swiss studies experienced any severe adverse events 
related to MDMA.
Research proposals are also being designed to inves-
tigate whether autism and Asperger’s syndrome can 
be treated with MDMA. Dr. Yazar-Klosinski is hopeful 
that in the future, psychiatrists will be able to prescribe 
MDMA clinically to patients for the treatment of PTSD, 
depression, and other psychiatric disorders.
Recent Findings from the Johns Hopkins Hallucinogen 
Research Group, by Matthew W. Johnson, PhD
“I left the session animated and intellectually stimu-
lated,” said Clark Martin when describing his first ses-
sion with psilocybin in the Johns Hopkins University pilot 
study for individuals suffering from anxiety and depres-
sion related to cancer. He noted, “Today, I don’t have a 
sense of death like I used to. . . . I don’t get too worked 
up about my illness anymore” (Zaitchik, 2011). Martin is 
a retired clinical psychologist who has undergone che-
motherapy, counseling, and antidepressants in his battle 
against renal cancer.
Matthew Johnson, PhD, an assistant professor of behav-
ioral pharmacology at Johns Hopkins, discussed seven 
ongoing or recently completed psychedelic research proj-
ects at the university, including the one in which Martin 
was enrolled. The initial Johns Hopkins clinical study on 
psilocybin investigated the effects of large doses of the 
drug on 36 high-functioning volunteers. The mean age 
of the participants was 46, and none of them had used 
hallucinogens prior to the study. Each volunteer received 
two sessions either with psilocybin or with the control 
drug, methylphenidate (Ritalin), which was selected for 
its ability to mimic the physical effects of psilocybin. Like 
the MDMA-assisted psychotherapy sessions described by 
Dr. Yazar-Klosinski, the psilocybin sessions took place in 
a comfortable room. Each session lasted eight hours and 
was conducted under the supervision of an “experienced 
guide” in case the volunteers became anxious or fright-
ened (Griffiths et al., 2008).
The experiences of the volunteers were evaluated using 
the Lifetime Mysticism Scale (LMS), a 32-item question-
naire that assesses primary mystical experiences. The LMS 
has been extensively studied and shows cross-cultural 
reliability, as well as sensitivity to psilocybin-based experi-
ences. Of the volunteers, 35% claimed that their sessions 
with psilocybin could be classified as the most significant 
spiritual experience of their lives, and 40% reported that 
the sessions were within their top five most significant 
lifetime experiences. According to self-reported ques-
tionnaires assessing changes in attitudes, mood, and 
social and other behaviors, these changes were still con-
sidered significant 2 and 14 months after the sessions.
In a second clinical study, volunteers underwent five 
sessions with psilocybin, spaced one month apart, but 
half of the volunteers received progressively increasing 
doses of psilocybin while the other half received pro-
gressively decreasing doses. Three weeks after the ses-
sions ended, the effects were assessed; the group that 
received increasing doses of psilocybin responded more 
favorably than the group that received decreasing doses. 
Seven participants (39%) experienced elements of a “bad 
trip” for a brief period of time during one of the sessions, 
and six of these subjects experienced these effects at the 
highest dose of psilocybin. The researchers noted that 
the chance of having a mystical experience at the highest 
dose of psilocybin is only 10% greater than at the next 
lower dose, although the chance to experience adverse 
effects is much greater. The subjects also reported dose-
dependent headaches (Griffiths et al., 2011).
A third study was similar to the first two, but its purpose 
was to measure changes in the personality dimension of 
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“openness” in subjects who had a “complete mystical 
experience” as defined by the LMS. Openness, as defined 
by the 240-item NEO Personality Inventory used in con-
temporary psychology to describe human personality, is 
based on an examination of various specific facets. These 
facets include fantasy (e.g., “I have a very active imagi-
nation”), aesthetics (e.g., “I am intrigued by patterns I 
find in art and nature”), feelings (e.g., “I experience a 
wide range of emotions and feelings”), ideas (e.g., “I 
often enjoy playing with theories or abstract ideas”), 
values (e.g., “I consider myself broad-minded and tol-
erant of other people’s lifestyles”), and actions (e.g., “I 
think it’s interesting to learn and develop new hobbies”). 
Each item was rated on a five-point scale ranging from 
“strongly disagree” to “strongly agree” (MacLean et al., 
2011). The results of this study showed that participants 
who had a mystical experience during a psilocybin ses-
sion had remained significantly more open compared to 
the control group more than a year later. This suggested 
to the Johns Hopkins researchers that psilocybin could 
be used for chronic conditions, such as the treatment of 
addiction and end-of-life issues in patients with terminal 
cancer.
An ongoing study at Johns Hopkins is measuring the 
effects of five psilocybin sessions on smoking cessation. 
While the data are preliminary, they demonstrate a sig-
nificant decline in smoking addiction among participants 
after the fifth session. Another psilocybin clinical study at 
Johns Hopkins was the one in which Martin, the retired 
clinical psychologist, was enrolled. Its aim was to deter-
mine whether treatment with psilocybin helps terminal 
cancer patients cope with end-of-life issues. The results 
were promising and suggest that psilocybin may play an 
important role in reducing the amount of anxiety expe-
rienced by patients with late-stage cancer (Grob 2011).
The results of these psilocybin studies have far-reach-
ing implications and pose many questions about the 
nature of consciousness. For their next psilocybin project, 
researchers at Johns Hopkins are planning to investigate 
the similarities and differences in states of conscious-
ness between individuals in deeply meditative states and 
those who are under the influence of psilocybin. At the 
conclusion of his presentation, Matthew Johnson left the 
audience with an important question to ponder: “If psilo-
cybin can help terminal cancer patients accept death and 
find new meaning in their lives, what should its role be in 
healthy individuals?”
POTENTIAL NEW HORIZONS?
For the current resurgence of psychedelic research to 
continue successfully, scientists and physicians must not 
become overly zealous and make the same mistakes 
that brought psychedelic research to a halt in the late 
1960s. Designing safe and carefully controlled research 
protocols under strict regulation by the FDA is critical for 
the continuing investigation of the potential therapeu-
tic applications of these drugs. As reliable and verifiable 
data continue to be generated by both basic science and 
clinical research studies, more questions will arise about 
the potential healing properties of psychedelics. The 
more questions that researchers can safely and ethically 
answer, the more treatments may become available for 
treating conditions ranging from PTSD to anxiety. If the 
research projects discussed at Judson Memorial Church 
during the fifth annual Horizons conference provide any 
indication of the promising ideas at work in the minds of 
today’s researchers and clinicians, then the future of psy-
chedelic research is sure to be an interesting one.
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